"APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer, a rANdomized trial -PERSIAN".

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501894-37-00

Acronym

PERSIAN

Enrollment

180

Registered

2023-02-20

Start date

2023-03-02

Completion date

Unknown

Last updated

2025-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Brief summary

Rate of patients with complete biochemical response (PSA < 0.2 ng/ml) at 6 months after treatment start

Detailed description

Freedom from biochemical progression according to Prostate Cancer Working Group Criteria, Freedom from radiological progression according to Prostate Cancer Working Group Criteria, Rate of adverse events, measured according to Common Terminology Criteria for Adverse Events, Overall Survival, Cancer Specific Survival, Health related quality of life measured with EORTC QLQ-C30 and QLQ-PR25 questionnaires

Interventions

DRUGAPALUTAMIDE

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Rate of patients with complete biochemical response (PSA < 0.2 ng/ml) at 6 months after treatment start	—

Secondary

Measure	Time frame
Freedom from biochemical progression according to Prostate Cancer Working Group Criteria, Freedom from radiological progression according to Prostate Cancer Working Group Criteria, Rate of adverse events, measured according to Common Terminology Criteria for Adverse Events, Overall Survival, Cancer Specific Survival, Health related quality of life measured with EORTC QLQ-C30 and QLQ-PR25 questionnaires	—

Measure

Time frame

—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026